BioMarin Pharmaceutical Inc.
) recently received positive news when the company's Biologics
License Application (BLA) for its pipeline candidate Vimizim
(BMN-110, elosulfase alfa) was accepted for review by the US Food
and Drug Administration (FDA).
The BLA was submitted to the FDA earlier in the year. We note
that BioMarin Pharma is seeking US approval of Vimizim
(previously known as GALNS), for the treatment of patients
suffering from mucopolysaccharidosis type IVA (MPS IVA) or
morquio A syndrome.
The FDA will review the BLA for Vimizim on a priority basis.
The FDA had requested for additional Chemistry, Manufacturing and
Controls (CMC) information from the company while conducting an
initial review. Upon receiving the required information from
BioMarin Pharma, the FDA designated it as a major amendment to
the application. Consequently, the Prescription Drug User Fee Act
(PDUFA) date was pushed back by three months to Feb 2014.
BioMarin Pharma is also seeking approval for Vimizim in the
European Union (EU) for the same indication. The European
Medicines Agency (EMA) recently validated BioMarin Pharma's
Marketing Authorization Application (MAA) for Vimizim, submitted
earlier in the year.
The EMA had earlier accepted BioMarin Pharma's request for
accelerated assessment for this MAA and the validation now allows
EMA to start its formal review process.
BioMarin Pharma expects an opinion from the EMA's Committee
for Medicinal Products for Human Use (CHMP) on Vimizim in Dec
2013. The company expects a decision from the European Commission
in the first quarter of 2014, provided the CHMP renders a
positive opinion on Vimizim.
We expect investor focus to stay on the regulatory updates on
Vimizim. We believe that an approval for Vimizin in both the US
and EU and subsequent successful commercialization will augment
BioMarin Pharma's portfolio.
BioMarin Pharma currently carries a Zacks Rank #3 (Hold).
Anika Therapeutics, Inc.
Aeterna Zentaris Inc
) look attractive with a Zacks Rank #1 (Strong Buy).
AETERNA ZENTARS (AEZS): Free Stock Analysis
ANIKA THERAPEUT (ANIK): Free Stock Analysis
BIOMARIN PHARMA (BMRN): Free Stock Analysis
GENTIUM SPA-ADR (GENT): Free Stock Analysis
To read this article on Zacks.com click here.